The MAA includes the efficacy and safety data of several studies involving over 4,000 patients, and also includes a long-term safety study with more than 600 patients.
Dymista is formulated with azelastine hydrochloride and fluticasone propionate and is used as a nasal spray formulation to treat moderate to severe allergic rhinitis and rhinoconjuctivitis.